Compare Ascendis Pharma A/S (ASND) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Solaredge Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Solaredge Technologies Inc trades at $51.69 (market cap $3.36B). The key difference: Ascendis Pharma A/S is far larger — about 5.3× Solaredge Technologies Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SEDG | |
|---|---|---|
Market Cap | $17.74B | $3.36B |
Sector | Health | Technology |
52-Week High | $277.18 | $78.51 |
52-Week Low | $163.32 | $24.42 |
Enterprise Value | $18.11B | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SolarEdge Technologies (SEDG) trades at $55.18, up 0.77% on the day, with a neutral technical signal and mixed analyst sentiment. The company shows improving operational cash flow ($104M in 2025) but continues to report significant losses (-$405M net income). Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, while solar sector momentum from AI data center demand provides tailwinds.
The stock faces fundamental challenges with negative margins and high debt, though cash flow stabilization and sector growth offer potential upside. Key risks include persistent profitability issues and policy uncertainty, while analyst consensus remains cautious with a $34.99 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
